Deep Value: cash covers more than 100% of the stock price

This company holds roughly $9M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Evogene

EVGN

Biotechnology · Healthcare

Price

$0.56

+0.00 (+0.36%)

Market Cap

$4.8M

Exchange

NASDAQ Global Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count falling — buybacks

−80.8% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 41.0M (2021) → 7.9M (2025)

Winston Score History

The full picture

Evogene is an Israeli biotechnology company that uses computational biology and artificial intelligence to develop new products for agriculture, medicine, and industrial uses. Its core platform, called GeneRator, helps design microbes, genes, and small molecules faster than traditional lab methods. The company works across several subsidiaries focused on areas like crop protection, crop seeds, human health drugs, and cannabis.

Evogene makes money mainly through research collaborations, licensing deals, and grants — not yet from large-scale product sales. It is headquartered in Rehovot, Israel, and operates as a small-cap company with a market cap near zero, meaning it is still in early-stage development. The company has been spending far more than it earns, as shown by its deeply negative operating margin, which is a significant risk. Its main growth driver is whether its AI-based platform can produce commercially successful products across its subsidiaries before it runs out of funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-60.7% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+77.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$8M/ year

↓ Declining (-36% vs prior year)

207.5% of revenue

11.5x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.0%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~13 months

$9M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Adequate runway but may need to raise capital within 2 years

Revenue declining

Evogene's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-2.3%

Thin — -2.3% gross margin

Profit after running costs

Operating Margin

-703.5%

Losing money on operations — -703.5%

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-80.4%

Shrinking sales (-80.4% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-884.4%

Burning cash (-884.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial